1:Hemophilia A carriers X 1 = log 10 (AHF activity) X 2 = log 10 - PowerPoint PPT Presentation

Oct 30, 2022 •265 likes •322 views

1:Hemophilia A carriers X 1 = log 10 (AHF activity) X 2 = log 10 (AHF-like antigen) : n 1 = 30 ; : n 2 = 22 0 . 0065 0 . 2483 x (1) = x (2) = , 0 . 0390 0 . 0262

� � � � 1:Hemophilia A carriers X 1 = log 10 (AHF activity) X 2 = log 10 (AHF-like antigen) � � � : n 1 = 30 ; � � � : n 2 = 22 � � � � − 0 . 0065 − 0 . 2483 x (1) = x (2) = ¯ , ¯ − 0 . 0390 0 . 0262 � � 131 . 158 − 90 . 423 S − 1 = p − 90 . 423 108 . 147 – p. 1/
� 1:Hemophilia A carriers (1) � ′ � x 0 − 1 x (1) + ¯ x (1) − ¯ x (2) ) S − 1 x (2) ) W ( − → → − x 0 ) = 2(¯ p (¯ = − 2 . 01 < 0 , x 0 = ( − 0 . 210 , − 0 . 044) ′ � � � � . � � , − → – p. 2/
� 1:Hemophilia A carriers (2) � p 1 = 0 . 25 , p 2 = 0 . 75 � , � ′ � x 0 − 1 x (1) + ¯ x (1) − ¯ W ( − → − → x (2) ) S − 1 x (2) ) x 0 ) = 2(¯ p (¯ � 0 . 25 � = − 2 . 01 < ln = − 1 . 10 , 0 . 75 x 0 = ( − 0 . 210 , − 0 . 044) ′ � � � � . � � , − → – p. 3/
GBKkai 3-1

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

Role of the Laboratory Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center

New Therapeutic Approaches to Hemophilia. The Role of the Laboratory Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS C Granda Maggiore Hospital Foundation and Humanitas University Milano, Italy Coagulation

658 views • 46 slides

Carriers for Pneumatic Tube Systems 63 mm, 90 mm, 110 mm, 160 mm Carriers for Pneumatic Tube

Hanter Ingenjrsteknik AB Carriers for Pneumatic Tube Systems 63 mm, 90 mm, 110 mm, 160 mm Carriers for Pneumatic Tube Systems 63 mm Capsule 63 Red Cpl Art. 6035200 Flight bags 63 Art. 6035101, purple Art. 6035102, dark red Art. 6035103, dark

394 views • 5 slides

IP over Web-Avian Carriers (IPoWAC) Dan Ldtke Historical Context IP over Avian Carriers

IP over Web-Avian Carriers (IPoWAC) Dan Ldtke Historical Context IP over Avian Carriers RFC 1149 RFC 2549 Write/print IP datagram on paper Attach paper to avian carrier e.g. homing pigeon MTU depends in

662 views • 11 slides

WORLD FEDERATION OF HEMOPHILIA Mark Brooker, WFH Senior Public Policy Officer London July 2,

WORLD FEDERATION OF HEMOPHILIA Mark Brooker, WFH Senior Public Policy Officer London July 2, 2015 PATIEN TS PER SPEC TIVE The World Federation of Hemophilia (WFH), an international not-for-profit organization, was established in 1963.

460 views • 10 slides

Carriers and Foreign Air Carriers April 25, 2017 Requirement to Consult The Port Authority

PFC Consultation Meeting with Air Carriers and Foreign Air Carriers April 25, 2017 Requirement to Consult The Port Authority of New York and New Jersey (Port Authority) intends to submit an application to the Federal Aviation

195 views • 18 slides

SB-525, A NOVEL GENE THERAPY FOR TREATMENT OF HEMOPHILIA A Kathleen Meyer MPH, PhD, DABT Sangamo

SB-525, A NOVEL GENE THERAPY FOR TREATMENT OF HEMOPHILIA A Kathleen Meyer MPH, PhD, DABT Sangamo Therapeutics NorCal SOT Meeting October 24, 2019 2 We are committed to translating ground-breaking science into genomic medicines that transform

596 views • 34 slides

Hemophilia in the newborn without family history: Pattern of clinical presentation of three

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/47728306 Hemophilia in the newborn without family history: Pattern of clinical presentation of three patients Article in Vojnosanitetski

404 views • 4 slides

Towards AAV5-mediated Gene Therapy for Hemophilia A with a Factor IX Variant that functions

Towards AAV5-mediated Gene Therapy for Hemophilia A with a Factor IX Variant that functions independently of FVIII Ying Poi Liu, PhD uniQure Biopharma B.V., Amsterdam, The Netherlands This presentation contains forward-looking statements. All

695 views • 20 slides

Private Insurance Changes and Resources and Self-Advocacy (Oh My!) Presented by: Michelle

HCCs 2019 Webinar Hemophilia Council of California series is sponsored Health Access, Advocacy , and Policy Webinar by: Private Insurance Changes and Resources and Self-Advocacy (Oh My!) Presented by: Michelle Rice, National Hemophilia

428 views • 18 slides

Appendix Potential target patient populations 2018 Oncology Hemophilia A Ophthalmology

Appendix Potential target patient populations 2018 Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 2 Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC) 2018 estimates for number of patients 3

531 views • 49 slides

EMA Workshop on Hemophilia Registries Industry Perspectives July 01-02, 2015 - London Mary

EMA Workshop on Hemophilia Registries Industry Perspectives July 01-02, 2015 - London Mary Gustafson Vice President Medical and Regulatory Policy Plasma Protein Therapeutics Association www.pptaglobal.org Industry Collaborators Birgit

152 views • 13 slides

Using Zinc Finger Nucleases for Subjects with Hemophilia B NIH Recombinant DNA Advisory Committee

Gene editing and Targeted Integration Using Zinc Finger Nucleases for Subjects with Hemophilia B NIH Recombinant DNA Advisory Committee September 9, 2015 Nadia Ewing, MD, City of Hope John A. Zaia, MD, City of Hope Dale Ando, MD, Sangamo

575 views • 31 slides

Study funding: Janssen Alzheimer Immunotherapy and Pfizer Inc 42 2 Key Biomarker Secondary

Bapineuzumab Phase 3 trials in mild to moderate Alzheimers disease dementia in apolipoprotein E e 4 carriers (Study 302) and non-carriers (Study 301) CSF and Volumetric MRI Biomarkers Nick C Fox, MD, FRCP Professor of Neurology, MRC Senior

296 views • 26 slides

Alaska Exchange Carriers Association Alaska Exchange Carriers Association February 10, 2012 1

Alaska Exchange Carriers Association Alaska Exchange Carriers Association February 10, 2012 1 How do current access charges fit in with the FCC s proposed transition to bill and keep? FCCs proposed transition to bill and keep? The

887 views • 10 slides

UMBC A B M A L T F O U M B C I M Y O R T 1 (December 4, 2000 6:10 pm) I E S

Principles of VLSI Design Details of the MOS Transistor CMSC 491B/711 MOS Transistor Definitions n-type MOS: Majority carriers are electrons. p-type MOS: Majority carriers are holes. Positive/negative voltage applied to the gate (with respect

503 views • 22 slides

Study funding: Janssen Alzheimer Immunotherapy and Pfizer Inc 19 2 Results: Safety 20 3

Bapineuzumab Phase 3 trials in mild to moderate Alzheimers disease dementia in apolipoprotein E e 4 carriers (Study 302) and non-carriers (Study 301) Safety and PiB PET Amyloid Imaging Sperling R, Salloway S, Raskind M, Ferris S, Honig L,

495 views • 23 slides

MDCL Modulation Dependent Carrier Level Agenda Overview Theory What is it? Jeff

MDCL Modulation Dependent Carrier Level Agenda Overview Theory What is it? Jeff Welton, CBRE Regional Sales Manager Central U.S. Benefits Why do it? Implementation How do we get it? Cris Alexander, CPBE Director

773 views • 24 slides

Speech Processing 11-492/18-492 Speech Processing 11-492/18-492 Speech Synthesis Evaluation

Speech Processing 11-492/18-492 Speech Processing 11-492/18-492 Speech Synthesis Evaluation Evaluating Speech Synthesis Evaluating Speech Synthesis How good is the voice? How good is the voice? This voice is a 45.67 This voice is a

461 views • 24 slides

Limited Benefit Health Insurance Plans Limited Benefit Health Insurance Plans For Individuals and

Limited Benefit Health Insurance Plans Limited Benefit Health Insurance Plans For Individuals and Families Exclusively for Members of the National Congress of Employers LIMITED MEDICAL INDEMNITY PLANS Benefit Benefits are based on an annual

395 views • 4 slides

5G Berlin an Open 5G Test-Field for early 5G Prototyping Thomas Haustein, Fraunhofer HHI,

5G-Berlin.org 5G Berlin an Open 5G Test-Field for early 5G Prototyping Thomas Haustein, Fraunhofer HHI, Wireless Communications and Networks 2 nd November 2016, Berlin, Germany 5G Berlin a Collaborative Research Initiative 5G

149 views • 11 slides

Cutting Edge Genetics Made Research funding, Natera Easy Consultant and advisory board

6/7/2018 Disclosures Cutting Edge Genetics Made Research funding, Natera Easy Consultant and advisory board member, Invitae Mary E Norton, MD Department of Obstetrics, Gynecology, and Reproductive Sciences University of California,

598 views • 17 slides

Total Cost of Care (TCOC) Workgroup September 25, 2019 Agenda Introductions & Updates 1.

Total Cost of Care (TCOC) Workgroup September 25, 2019 Agenda Introductions & Updates 1. Y2 & Y3 MPA (PY19) 2. Y2 Updates i. Potential MPA Y3 Policy Changes ii. Churn Analysis (Y4) iii. MPA Framework 3. Comments from Draft

480 views • 47 slides

trt rr s

trt rr s Pttr t , sr rtr rst

868 views • 60 slides

Cascades and Contagion Prof. Srijan Kumar http://cc.gatech.edu/~srijan 1 Srijan Kumar, Georgia

CSE 6240: Web Search and Text Mining. Spring 2020 Cascades and Contagion Prof. Srijan Kumar http://cc.gatech.edu/~srijan 1 Srijan Kumar, Georgia Tech, CSE6240 Spring 2020: Web Search and Text Mining Administrivia Proposal grades are out

507 views • 49 slides